Literature DB >> 1388043

Leukemia in Down syndrome: a review.

A Zipursky1, A Poon, J Doyle.   

Abstract

The incidence of leukemia is higher in children with Down syndrome (DS) than in normals. In approximately 50% of cases the type of leukemia is acute megakaryoblastic leukemia (AMKL) and it occurs during the first 4 years of life. The leukemic cell also has features of erythroid progenitors and therefore appears to be a precursor cell with biphenotypic properties. In addition, newborns with DS frequently develop transient leukemia (TL), which is characterized by the presence of megakaryoblasts in the blood which disappear during the first 1-3 months of life. The incidence of this disorder is unknown although preliminary studies suggest that megakaryoblasts may be found frequently in the blood of DS newborns. TL does not occur in normal newborn infants. Although TL disappears spontaneously, many of these children will develop AMKL at 1-4 years of age. Recent surveys suggest that 20-30% of newborns with TL will develop AMKL. Preliminary evidence suggests that TL is a clonal proliferation, can be fatal, and may occur in a specific subgroup of DS children. The observations in this report are drawn from our own experience, reports in the literature, and data accumulated in the Canadian Down Syndrome Leukemia Registry.

Entities:  

Mesh:

Year:  1992        PMID: 1388043     DOI: 10.3109/08880019209018329

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  29 in total

1.  Life-threatening complications of transient abnormal myelopoiesis in neonates with Down syndrome.

Authors:  Sabine Dormann; Marcus Krüger; Roland Hentschel; Regina Rasenack; Brigitte Strahm; Udo Kontny; Charlotte Niemeyer
Journal:  Eur J Pediatr       Date:  2004-04-28       Impact factor: 3.183

Review 2.  Topics in pediatric leukemia--acute lymphoblastic leukemia.

Authors:  Samuel D Esparza; Kathleen M Sakamoto
Journal:  MedGenMed       Date:  2005-03-07

Review 3.  Topics in pediatric leukemia--acute myeloid leukemia.

Authors:  Jerry Cheng; Kathleen M Sakamot
Journal:  MedGenMed       Date:  2005-03-21

4.  JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.

Authors:  Thomas Mercher; Gerlinde Wernig; Sandra A Moore; Ross L Levine; Ting-Lei Gu; Stefan Fröhling; Dana Cullen; Roberto D Polakiewicz; Olivier A Bernard; Titus J Boggon; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

Review 5.  Evolution of myeloid leukemia in children with Down syndrome.

Authors:  Satoshi Saida
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

Review 6.  Down syndrome and the complexity of genome dosage imbalance.

Authors:  Stylianos E Antonarakis
Journal:  Nat Rev Genet       Date:  2016-12-28       Impact factor: 53.242

7.  Precocious clonal hematopoiesis in Down syndrome is accompanied by immune dysregulation.

Authors:  L Alexander Liggett; Matthew D Galbraith; Keith P Smith; Kelly D Sullivan; Ross E Granrath; Belinda Enriquez-Estrada; Kohl T Kinning; Jessica R Shaw; Angela L Rachubinski; Joaquin M Espinosa; James DeGregori
Journal:  Blood Adv       Date:  2021-04-13

8.  Leukemogenesis caused by incapacitated GATA-1 function.

Authors:  Ritsuko Shimizu; Takashi Kuroha; Osamu Ohneda; Xiaoqing Pan; Kinuko Ohneda; Satoru Takahashi; Sjaak Philipsen; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

9.  Isolation of a cosmid clone corresponding to an inv(21) breakpoint of a patient with transient abnormal myelopoiesis.

Authors:  T Ohta; M Nakano; T Tsujita; K Abe; K Osoegawa; T Yamagata; K Yoshiura; Y Jinno; E Soeda; Y Nakamura; N Niikawa
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

10.  Human genes involved in copy number variation: mechanisms of origin, functional effects and implications for disease.

Authors:  A J de Smith; R G Walters; P Froguel; A I Blakemore
Journal:  Cytogenet Genome Res       Date:  2009-03-11       Impact factor: 1.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.